(Q36953131)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898706%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Endocannabinoid system and cardiometabolic risk (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898706%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

main subject

endocannabinoid system

0 references

author

Leonardo Saavedra

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898706%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

L E Saavedra

series ordinal

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

26 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898706%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898706%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898706%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898706%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

591-594

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17898706%20AND%20SRC:MED&resulttype=core&format=json

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Adipose tissue and adipokines: for better or worse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

The metabolic syndrome--a new worldwide definition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

The endocannabinoid system: a general view and latest additions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

The endocannabinoid system and its therapeutic exploitation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021

Smoking cessation: lessons learned from clinical trial evidence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100373

7 January 2021